BioSpace News Archive

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has entered into a new funded collaboration with a large pharmaceutical company to add novel mechanisms for oral peptide formulations within the top-rated GastroPlus® Advanced Compartmental Absorption and Transit (ACAT™) mechanistic mode

Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announced that Prof. Luigi Naldini, Co-Founder and Chairman of its Executive Scientific Board, will take part in a gene therapy panel discussion at the LifeSci Partners 10 th Annual Healthcare Corporate Access Event which is being held virtually from January 6-8 and 11-14. The panel,

Marrone Bio Innovations, Inc. (NASDAQ: MBII), a leading provider of effective and environmentally responsible pest management and plant health products, today provided an update on its warrant transactions. Effective Dec. 29, 2020, an amendment was made to a prior warrant agreement with Van Herk Investments that extends the maturities of its existing warrants. As a result, Van Herk exercised 33.3% of its outstanding warrants, reducing the tot

Inhibrx, Inc. (Inhibrx), a clinical-stage biotechnology company with a broad pipeline of biotherapeutics in development, announced today results from Part 1 of the Phase 1 dose escalation trial of INBRX-106, a novel hexavalent OX40 agonist, in development for the treatment of solid tumors.

Therapix Biosciences Ltd. (OTCQB: TRPXY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced it has entered a non-binding letter of intent with Cy

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has granted a stock option to purchase 75,000 shares of common stock to one new employee. The stock option was granted pursuan

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will webcast a live presentation at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 12, 2021 at 12:40 p.m. PT ( 3:40 p.m. ET ).

Brightseed Announces Preclinical Data For Phytonutrients Targeting Liver and Metabolic Health AI-Powered Discovery Shows Novel Biological Mechanism, Moves Into Clinical Trials in 2021

Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva® Advanced Cervical Scan, based on its patented biophotonic technology, announced today that it had received a new purchase order in the amount of $530,695 from its Chinese co-manufacturing partner and distributor for China, Shandong Yaohua Medical Instrument Corporation (SMI). The new purchase order, which was issued by SMI based on its progress with

Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company progressing Nano-Pulse Stimulation TM (NPS™) technology, announced today that on December 31, 2020, it delivered a notice of redemption to redeem all of its outstanding warrants (the “Warrants”) to purchase shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), issued on June